Quarterly ResultAug 4, 2026, 06:08 AM
IDEAYA Biosciences Q2 Net Loss $112.5M; Darovasertib Trial Met Endpoint
AI Summary
IDEAYA Biosciences reported its second quarter 2026 financial results, with a net loss of $112.5 million and collaboration revenue of $8.9 million. The company announced that its registrational OptimUM-02 trial for the darovasertib combination in metastatic uveal melanoma met its primary endpoint, with an NDA filing underway. IDEAYA ended the quarter with approximately $1.24 billion in cash, cash equivalents, and marketable securities, supported by $323.4 million in net proceeds from a recent public offering, extending its cash runway into 2030. The company also highlighted upcoming data presentations at ESMO and a new clinical collaboration with Roche for IDE892.
Key Highlights
- Registrational OptimUM-02 trial for darovasertib met its primary endpoint.
- Q2 2026 net loss was $112.5 million.
- Cash, cash equivalents, and marketable securities totaled $1.24 billion as of June 30, 2026.
- Cash runway guidance extends into 2030.
- Collaboration revenue for Q2 2026 was $8.9 million.
- R&D expenses for Q2 2026 increased to $108.7 million.
- Net proceeds from June public offering were $323.4 million.
- Clinical collaboration with Roche initiated for IDE892 in pancreatic cancer.
Price Impact
More from IDYA